Cost Minimization Analysis Of Clinical Option Scenarios For Metformin And Acarbose In Treatment Of Type 2 Diabetes: Based On Direct And Indirect Treatment Comparison Results

Value in Health ◽

10.1016/j.jval.2014.08.165 ◽

2014 ◽

Vol 17 (7) ◽

pp. A745 ◽

Author(s):

S Gu ◽

X Xu ◽

L Shi ◽

M Sawhney ◽

H Hu ◽

...

Keyword(s):

Type 2 Diabetes ◽

Cost Minimization ◽

Indirect Treatment Comparison ◽

Cost Minimization Analysis ◽

Treatment Comparison ◽

Comparison Results ◽

Indirect Treatment

Download Full-text

Efficacy and Safety of Eight Classes of Glucose-Lowering Agents as Monotherapy for Type 2 Diabetes: A Systematic Review and Indirect Treatment Comparison

SSRN Electronic Journal ◽

10.2139/ssrn.3539644 ◽

2020 ◽

Author(s):

Shuyan Gu ◽

Xueshan Sun ◽

Xiaoqian Hu ◽

Lizheng Shi ◽

Minzhuo Huang ◽

...

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Efficacy And Safety ◽

Glucose Lowering ◽

Indirect Treatment Comparison ◽

Treatment Comparison ◽

Indirect Treatment

Download Full-text

Review for "Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists (GLP-1RAs): a systematic literature review and indirect treatment comparison"

10.1111/dom.14136/v1/review3 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Literature Review ◽

Systematic Literature Review ◽

Efficacy And Safety ◽

Indirect Treatment Comparison ◽

Treatment Comparison ◽

Indirect Treatment ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Once-daily liraglutide (1.2 mg) compared with twice-daily exenatide (10 μg) in the treatment of type 2 diabetes patients: An indirect treatment comparison meta-analysis

Journal of Diabetes ◽

10.1111/1753-0407.12372 ◽

2016 ◽

Vol 8 (6) ◽

pp. 866-876 ◽

Author(s):

Stephen M. Twigg ◽

Mirella M. Daja ◽

Beth A. O’leary ◽

Michael A. Adena

Keyword(s):

Type 2 Diabetes ◽

Meta Analysis ◽

Indirect Treatment Comparison ◽

Treatment Comparison ◽

Indirect Treatment ◽

Diabetes Patients

Download Full-text

PDB17 INDIRECT TREATMENT COMPARISON OF SGLT2 INHIBITOR MONOTHERAPY IN PATIENTS WITH UNCONTROLLED TYPE 2 DIABETES ON DIET/EXERCISE OR METFORMIN

Value in Health ◽

10.1016/j.jval.2019.04.567 ◽

2019 ◽

Vol 22 ◽

pp. S142-S143

Author(s):

P. Pandey ◽

R. Pandey ◽

P. Dhagale ◽

V. Shah

Keyword(s):

Type 2 Diabetes ◽

Sglt2 Inhibitor ◽

Indirect Treatment Comparison ◽

Treatment Comparison ◽

Indirect Treatment

Download Full-text

Review for "Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists (GLP-1RAs): a systematic literature review and indirect treatment comparison"

10.1111/dom.14136/v2/review1 ◽

2020 ◽

Author(s):

Viral Shah

Keyword(s):

Type 2 Diabetes ◽

Literature Review ◽

Systematic Literature Review ◽

Efficacy And Safety ◽

Indirect Treatment Comparison ◽

Treatment Comparison ◽

Indirect Treatment ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin

Journal of Medical Economics ◽

10.1080/13696998.2017.1409228 ◽

2017 ◽

Vol 21 (4) ◽

pp. 340-347 ◽

Author(s):

Marc Evans ◽

Liana K. Billings ◽

Jonas Håkan-Bloch ◽

Ulla Slothuus ◽

Trine J. Abrahamsen ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Basal Insulin ◽

Insulin Degludec ◽

Indirect Treatment Comparison ◽

Treatment Comparison ◽

Indirect Treatment

Download Full-text

Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon‐like peptide‐1 receptor agonists: a systematic literature review and indirect treatment comparison

Diabetes Obesity and Metabolism ◽

10.1111/dom.14136 ◽

2020 ◽

Vol 22 (11) ◽

pp. 2170-2178 ◽

Author(s):

Philip D. Home ◽

Vanita R. Aroda ◽

Lawrence Blonde ◽

Patricia Guyot ◽

Alka Shaunik ◽

...

Keyword(s):

Type 2 Diabetes ◽

Literature Review ◽

Systematic Literature Review ◽

Efficacy And Safety ◽

Indirect Treatment Comparison ◽

Treatment Comparison ◽

Indirect Treatment ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Comparative Efficacy and Safety of Glucose-Lowering Drugs as Monotherapy for Type 2 Diabetes: A Systematic Review and Indirect Treatment Comparison

SSRN Electronic Journal ◽

10.2139/ssrn.3918870 ◽

2021 ◽

Author(s):

Shuyan Gu ◽

Xiaoqian Hu ◽

Xuemei Zhen ◽

Lizheng Shi ◽

Xueshan Sun ◽

...

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Efficacy And Safety ◽

Comparative Efficacy ◽

Glucose Lowering ◽

Indirect Treatment Comparison ◽

Treatment Comparison ◽

Indirect Treatment

Download Full-text

Review for "Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists (GLP-1RAs): a systematic literature review and indirect treatment comparison"

10.1111/dom.14136/v1/review1 ◽

2020 ◽

Author(s):

Viral Shah

Keyword(s):

Type 2 Diabetes ◽

Literature Review ◽

Systematic Literature Review ◽

Efficacy And Safety ◽

Indirect Treatment Comparison ◽

Treatment Comparison ◽

Indirect Treatment ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Review for "Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists (GLP-1RAs): a systematic literature review and indirect treatment comparison"

10.1111/dom.14136/v2/review3 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Literature Review ◽

Systematic Literature Review ◽

Efficacy And Safety ◽

Indirect Treatment Comparison ◽

Treatment Comparison ◽

Indirect Treatment ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text